Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genmab ( (GMAB) ) has provided an announcement.
In February 2025, Genmab A/S announced its 2024 annual report, highlighting significant achievements like the acquisition of ProfoundBio, which expanded its clinical candidates and novel ADC platforms. The report also emphasized Genmab’s commitment to sustainability and social responsibility, as demonstrated by its first ESG disclosures in line with the EU’s CSRD. The company celebrated its 25th anniversary with notable expansion in its leadership team, positioning itself for future growth and innovation in the biotech industry.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark that specializes in the discovery and development of antibody-based medicines. The company focuses on innovative therapeutics aimed at transforming the lives of patients with cancer and other serious diseases. Genmab is recognized for its global impact with eight antibody-based medicines and a strong pipeline, including two wholly owned assets now in late-stage development.
YTD Price Performance: -10.05%
Average Trading Volume: 1,360,531
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.07B
Learn more about GMAB stock on TipRanks’ Stock Analysis page.
